Content about Lipitor

January 25, 2011
Mylan announces Lipitor, Caduet patent settlements

Generic drug maker Mylan has entered settlements with Pfizer concerning two drugs for treating cholesterol.

PITTSBURGH — Generic drug maker Mylan has entered settlements with Pfizer concerning two drugs for treating cholesterol.

Mylan announced Tuesday that it had settled patent litigation suits with Pfizer concerning Lipitor (atorvastatin calcium) and Caduet (atorvastatin calcium and amlodipine besylate).

Under the Caduet agreement, the lawsuit will be dismissed, and Mylan can launch its generic version on Nov. 30. Terms of the Lipitor agreement remain confidential.

January 5, 2011
Pfizer seeks to stop generic versions of Lipitor

A generic version of the world’s top-selling cholesterol treatment is expected to hit the market this year, but the branded version’s manufacturer is trying to put the brakes on the launch, according to media reports.

NEW YORK — A generic version of the world’s top-selling cholesterol treatment is expected to hit the market this year, but the branded version’s manufacturer is trying to put the brakes on the launch, according to media reports.

Gurgaon, India-based Ranbaxy Labs plans to launch its version of Pfizer’s cholesterol-lowering drug Lipitor (atorvastatin) in the United States in November and will receive six months’ market exclusivity in which to compete directly against Pfizer’s version, under the terms of the Hatch-Waxman Act of 1984.

November 14, 2010
Countdown to 2011: A big year for generics

The world of generic drugs has a big year ahead of it. Actually, it has...

The world of generic drugs has a big year ahead of it. Actually, it has a few big years ahead of it. But 2011 in particular carries a certain symbolic value as the year in which Pfizer, the world’s biggest drug maker, loses control of its patent for the cholesterol-lowering drug Lipitor (atorvastatin calcium), the world’s top-selling drug.

September 26, 2010
NACDS conference discusses patent cliff, future of generics

Winc Design is launching its Charlie Banana brand of environmentally friendly cloth diapers and baby...

Like a freighter in the Atlantic Ocean during hurricane season, anyone with a stake in the generic drug industry will encounter smooth and bumpy sailing alike over the next few years, according to a recent presentation by an industry expert.

August 30, 2010
IMS Health exec to NACDS conference attendees: Expect opportunities, uncertainties for drug market

The U.S. drug market will present opportunities as well as uncertainties over the next decade,...

SAN DIEGO The U.S. drug market will present opportunities as well as uncertainties over the next decade, according to remarks made by IMS Health VP industry relations Doug Long at the National Association of Chain Drug Stores’ 2010 Pharmacy and Technology Conference held here on Monday.

 

October 18, 2009
Pfizer returns to consumer care with Wyeth buy

What’s really intriguing behind the return of a consumer division to Pfizer is the fact...

NEW YORK What’s really intriguing behind the return of a consumer division to Pfizer is the fact that two of its flagship pharmaceuticals -- Lipitor and Viagra -- are approaching patent expiration, and both have been suggested as possible Rx-to-OTC switch candidates by Kline & Co.